Day :
- Stem Cell Therapy | Regenerative Medicine | Mesenchymal Stem Cells |Tissue Bio-Engineering |Nanotechnology in Tissue Engineering|Induced Pluripotent Stem Cell | Skin Rejuvenation | Organ Regeneration
Location: Scandic Järvenpää | Helsinki, Finland
Chair
Joel Isaias Osorio Garcia
RegenerAge, USA
Co-Chair
Kristine Freude
BrainStem, Denmark
Session Introduction
Zaid Matti
Australasian Faculty of Musculoskeletal Medicine, New Zealand
Title: Platelet-rich plasma in musculoskeletal medicine
Biography:
Zaid Matti is a Musculoskeletal Medicine Practitioner. He has special interest in regenerative medicine with focus on ultrasound guided platelets rich plasma PRP and prolotherapy injections. He has completed his Graduation from the University of Baghdad Medical school in 2006. He has been trained in Orthopaedic Surgery at multiple hospitals in New Zealand and also had training in family medicine and emergency care. He is the Member of the Educational Committee of the Australasian Faculty of Musculoskeletal Medicine. He has completed his Post graduation study in Surgical Anatomy and Musculoskeletal Medicine from University of Otago in New Zealand.
Abstract:
Platelet-Rich Plasma (PRP) is one of many new developments within the field of regenerative medicine. Medical practitioners in areas such as musculoskeletal pain medicine, physical medicine and rehabilitation and rheumatology have been exploring the benefits of this novel therapy. The idea of using platelet-rich plasma in medicine has been around since the 1980’s. Its use has been employed in the area of musculoskeletal medicine recently in the past few years. Platelet-rich plasma in this field has received much media attention due to being used by many celebrity sports athletes for sports injuries. PRP is a promising treatment for some musculoskeletal conditions; However, evidence of its efficacy has been highly variable depending on the specific indication. Therefore, it is essential for practitioners to be aware of the concepts surrounding their use and application. The presentation will cover what platelet-rich plasma is? How is it prepared and administered? Its potential clinical application, and what the current literature discusses in the various areas of clinical musculoskeletal medicine and rehabilitation.
Zaid Matti
Australasian Faculty of Musculoskeletal Medicine, New Zealand
Title: Platelet-rich plasma in musculoskeletal medicine
Biography:
Zaid Matti is a Musculoskeletal Medicine Practitioner. He has special interest in regenerative medicine with focus on ultrasound guided platelets rich plasma PRP and prolotherapy injections. He has completed his Graduation from the University of Baghdad Medical school in 2006. He has been trained in Orthopaedic Surgery at multiple hospitals in New Zealand and also had training in family medicine and emergency care. He is the Member of the Educational Committee of the Australasian Faculty of Musculoskeletal Medicine. He has completed his Post graduation study in Surgical Anatomy and Musculoskeletal Medicine from University of Otago in New Zealand.
Abstract:
Platelet-Rich Plasma (PRP) is one of many new developments within the field of regenerative medicine. Medical practitioners in areas such as musculoskeletal pain medicine, physical medicine and rehabilitation and rheumatology have been exploring the benefits of this novel therapy. The idea of using platelet-rich plasma in medicine has been around since the 1980’s. Its use has been employed in the area of musculoskeletal medicine recently in the past few years. Platelet-rich plasma in this field has received much media attention due to being used by many celebrity sports athletes for sports injuries. PRP is a promising treatment for some musculoskeletal conditions; However, evidence of its efficacy has been highly variable depending on the specific indication. Therefore, it is essential for practitioners to be aware of the concepts surrounding their use and application. The presentation will cover what platelet-rich plasma is? How is it prepared and administered? Its potential clinical application, and what the current literature discusses in the various areas of clinical musculoskeletal medicine and rehabilitation.
Omid Panahi
Yeditepe University, Turkey
Title: Nanotechnology, regenerative medicine and tissue bio-engineering
Biography:
Omid Panahi has completed his Graduation from Centro Escolar University on Doctor of Dental Medicien and MSc in Oral and Maxillofacial surgery from Yeditepe University, Istanbul, Turkey. He has published more than 40 papers in reputed journals and has been serving as an Editorial Board Member of ISI journals.
Abstract:
The Appearance of Regenerative Medicine (RM) and Tissue Engineering (TE) opened new areas in medical science. These rapidly expanded field focus on the restoring function of damaged tissues and organs. Due to their multidisciplinary identity, RM and TE are in close relationship with stem cell biology, cellular therapy, bioengineering and nanotechnology. The nanotechnology has provided new structure with special biochemical, mechanical and electrical properties. With the advancement in nanotechnology direct connection with cell has become possible which offers exciting possibilities in medical therapy.
Biography:
Purwati has completed her General Practition in Internal Medicine from Universitas Airlangga. She has also completed her Doctoral program from Universitas Airlangga. Her interest is in stem cell field. She has worked as a Secretary of Stem Cell Laboratory of Universitas Airlangga and also as a Secretary of Surabaya Regenerative Medicine Centre. She is currently the Chairman of Stem Cell Research and Development Center Universitas Airlangga, Surabaya, Indonesia. She has 60 publication in journals, papers.
Abstract:
Skin aging is natural process where renewal of skin cells and collagen production slows down, as well as the weakening of internal support structure and natural protective layer of skin. Several anti-aging therapies are widely used in dealing with aging. Stem cell metabolites are rich in growth factors such as cytokines IL-10, IL-4, EGF, GM-CSF and TGF-β. These cytokines can penetrate skin layer to stimulate the growth of new cells and increase nutrition, accelerate skin metabolism to inhibit premature aging, stimulate skin to produce new proteins, collagen and elastic fibers, also reduce black pigments. Previous research focuses on in vitro and animal study of stem cell metabolites derived from placenta for skin regeneration. This study is an advanced stage by focusing on clinical trial in 30 patients who met the inclusion and exclusion criteria to be applied with stem cell metabolites on their face. Subjects were examined their face conditions by using janus skin analyzer to see markers on their skin and applied stem cell metabolites in their face twice per day, at day and night with single-use doses of three pumping. Evaluation was carried out before and after application of stem cell metabolites using janus in six weeks. The results of janus examination evaluated were spot, pore, roughness, wrinkle, UV acne, UV spot and UV moisture. The percentage of spot, pore, roughness, wrinkle, UV acne and UV spots are decreased, while the percentage of UV moisture is increased in almost all subjects who were evaluated for six weeks. In qualitative, almost 90% subjects are satisfied with the results of the application of stem cell metabolites. The subjects felt that facial wrinkles were reduced, the face was smoother and supple and pigmentation was reduced. It can be concluded that stem cell metabolites formula are effective and efficient in skin regeneration.
Mirolyuba Simeonova Ilieva
University of Southern Denmark, Denmark
Title: Patients derived iPSC and brain organoids in translational psychiatric research
Biography:
Mirolyuba Simeonova Ilieva is a Cell Biologist and has completed her PhD in Bio-Medical Nanotechnology at the Danish Technical University. She is a Research Coordinator in the Patients Centered Laboratory of Translational Psychiatry. She is developing new scientific direction in the Department of Psychiatry, University of Southern Denmark-patients derived iPSC and brain organoids for modeling neurodevelopmental psychiatric disorders.
Abstract:
Since their discovery induced pluripotent stem cells (iPSC) offered a new highway for regenerative medicine and the development of new strategies for disease treatment. On the other hand, iPSC derived from patients with specific pathology gives new perspectives for elucidating intimate mechanisms of the disease and development individualized and more effective treatment. The biggest challenge for psychiatric research at present is the lack of an appropriate link between cellular and molecular findings with the clinical symptoms. An important aspect of understanding the neurobiology of psychiatric disorders is to test the utility of the findings in the diagnostic process, which may establish such findings as biomarkers. Therefore the development of new concepts for disease modeling in the field of psychiatry and the creation of relevant humanized in vitro models as a base for downstream research is of a high need. Brain organoids generated from iPSC recapitulate the dynamics of neurogenesis, cellular variety, and intercellular communication which are affected in neurodevelopmental psychiatric disorders such as autism. They have the ability to recreate the right complexity of the brain. On the cellular, protein and gene expression level, organoids demonstrate a high similarity to the neurodevelopment in vivo and can, therefore, recapitulate early stages of the neurogenesis. Brain organoids represent a new tool for high throughput screening of chemical compounds and move forward the development of individualized drug treatment. Finally, the same platform could be used in these individuals, who are at high risk for the development of psychiatric disorders and elucidate the etiology, based on risk factor genes.
Orianne Domenge
University of Lyon, France
Title: Chitosan physical hydrogels for the regeneration of infarcted myocardium
Biography:
Orianne Domenge has completed her Engineering degree in Chemistry and Process Engineering from CPE Lyon (Higher School of Chemistry, Physics and Electronics) and a Specialization in Biochemistry. She is currently pursuing her PhD in Biomaterials in IMP laboratory (Polymer Materials Engineering) and is working on the development of bio-functionalized polysaccharide patches in order to improve myocardial function after infarction.
Abstract:
Myocardial infarction occurs as a consequence of an obstruction of blood vessels supplying the heart (coronary arteries). This leads to the death of myocardial cells (cardiomyocytes). The damaged tissue does not repair spontaneously and scar tissue is formed instead, as the mature contracting cardiac cells have limited capacity to proliferate. The objective of this project is to develop bio-functionalized hydrogel patches that will allow regeneration and functional recovery of the cardiac muscle after myocardial infarction. The strategy is to associate polysaccharide-based hydrogels and trophic factors (proteins), so as to develop cardiac patches capable of inducing beneficial effects for tissue regeneration. More precisely, chitosan physical hydrogels were performed by a NaOH induced-gelation process. Thus, bio functionalized patches were produced varying in composition (polysaccharide concentration, degree of acetylation of chitosan, etc.) and characterized, in particular in terms of mechanical properties, as in the final application, gels will be sutured on the injured tissue. Cardiomyocytes were cultured in vitro on hydrogels to assess the effect of patch composition on the survival and proliferation of cells. Chitosan hydrogel patches were also tested in vivo using a rat model of myocardial infarction. Our results illustrate the beneficial effect of optimized chitosan hydrogel patches in the regeneration and functional recovery of the cardiac tissue after infarction.
Amod Kulkarni
University of Veterinary Medicine and Pharmacy in Kosice, Slovakia
Title: Mapping of binding sites on NadA protein of Neisseria meningitidis and blocking its interaction with human brain microvascular endothelial cells
Biography:
Amod Kulkarni has completed his PhD in Biosciences from Nord University, Bodo, Norway and has been a Postdoctoral Researcher at the Laboratory of Biomedical Microbiology and Immunology, UVLF, Kosice, Slovakia since April 2018. He has published his research in 15 papers in reputed journals and has been an active Researcher in the field of host-pathogen interactions.
Abstract:
Nisseria meningitidis casing cererospinal meningitis utilizes several of its membrane proteins to interact with human Brain Microvascular Endothelial Cells (BMECs). Nisseria adhesin A -NadA an outer membrane protein has been recognized to mediate adhesion of bacteria and evokes strong bactericidal antibodies when used as vaccine candidate. In the present study, binding pockets of NadA (domains) interacting with the receptors of BMECs were mapped using mass spectrometry. In brief, binding of BMECs proteins and recombinant NadA (rNadA) expressed in E. coli M15 cells was determined by western blotting. On membrane tryptic digestion (partial) was performed and the non-interacting rNadA fragments were washed to retain BMEC protein-rNadA peptide complex. Further, mild striping was performed on the complex to isolate the domains of rNadA from BMEC proteins. MALDI-TOF/MS was employed to identify the amino acid sequences of the domains. Next, synthetically produced NadA peptides (37 mer peptides) corresponding to the interacting domains of rNadA were used to capture single domain antibodies (VHH) raised against rNadA through M13K07ΔpIII hyper phage system. At least 96 VHH clones were found to have an affinity for rNadA peptide 1 and 2. Among them 20 clones were tested for blocking the interaction of rNadA with BMEC proteins. However, only two clones of VHH binding to globular domain of rNadA and one clone of VHH binding to coiled coil region were able to block the interaction of rNadA with hBMEC proteins.
- Cell Therapy | Stem Cell Therapy | Cancer Therapy | Wound Care | 3D Culture | Bone Tissue Engineering | Biomaterials
Location: Scandic Jarvenpaa | Helsinki, Finland
Session Introduction
Claire Saucourt
CellProthera, France
Title: Expanded CD34+ cells for cardiac cell therapy
Biography:
Claire after a Phd. in cell biology, she joined the team of founders of CellProthera in 2009 and participated with her team to scientific works including the design and development of the StemXpand and the surrounding process. As project manager, and in collaboration with the CMO, she is an active element in the preparation of international clinical trials and participates to discussions with various regulatory authorities. In collaboration with the CDO, she is currently involved in the development of the future commercial device and the complete characterization of the process.
Abstract:
Background: We previously demonstrated that intra-cardiac delivery of autologous peripheral blood-CD34+ stem cells, mobilized by granulocyte-colony stimulating factor (G CSF) and collected by leukapheresis after myocardial infarction, structurally and functionally repaired the damaged myocardial area. When used for cardiac indication, CD34+ cells are now considered as ATMP (Advanced Therapy Medicinal Product). We have industrialized their production by developing an automated device for ex-vivo CD34+ stem cell expansion, starting from a whole blood sample. Method: Blood samples were collected from healthy donors after G-CSF mobilization. Manufacturing procedures included: (1) isolation of total nuclear cells (2) CD34+ immunoselection (3) expansion and cell culture recovery in the device and (4) expanded CD34+cell immunoselection and formulation. The assessment of CD34+ cell counts, viability and immunophenotype and sterility tests were performed as quality tests. Result: We established graft acceptance criteria and performed validation processes in three cell therapy centers (CTCs). 59.4±36.8×106 viable CD34+ cells were reproducibly generated as the final product from 220 mL whole blood containing 17.1±8.1x106 viable CD34+ cells. CD34+ identity, genetic stability and telomere length were consistent with those of basal CD34+ cells. Gram staining and mycoplasma and endotoxin analyses were negative in all cases. We confirmed the therapeutic efficacy of both CD34±cell categories in experimental AMI (Acute Myocardial Infarct) in immuno-deficient rats during pre-clinical studies. Discussion: This reproducible, automated, and standardized expansion process produces high numbers of CD34+ cells corresponding to the approved ATMP and paves the way for a phase I/IIb study in AMI, which is currently recruiting patients.
Biography:
Claire after a Phd. in cell biology, she joined the team of founders of CellProthera in 2009 and participated with her team to scientific works including the design and development of the StemXpand and the surrounding process. As project manager, and in collaboration with the CMO, she is an active element in the preparation of international clinical trials and participates to discussions with various regulatory authorities. In collaboration with the CDO, she is currently involved in the development of the future commercial device and the complete characterization of the process.
Abstract:
Background: We previously demonstrated that intra-cardiac delivery of autologous peripheral blood-CD34+ stem cells, mobilized by granulocyte-colony stimulating factor (G CSF) and collected by leukapheresis after myocardial infarction, structurally and functionally repaired the damaged myocardial area. When used for cardiac indication, CD34+ cells are now considered as ATMP (Advanced Therapy Medicinal Product). We have industrialized their production by developing an automated device for ex-vivo CD34+ stem cell expansion, starting from a whole blood sample. Method: Blood samples were collected from healthy donors after G-CSF mobilization. Manufacturing procedures included: (1) isolation of total nuclear cells (2) CD34+ immunoselection (3) expansion and cell culture recovery in the device and (4) expanded CD34+cell immunoselection and formulation. The assessment of CD34+ cell counts, viability and immunophenotype and sterility tests were performed as quality tests. Result: We established graft acceptance criteria and performed validation processes in three cell therapy centers (CTCs). 59.4±36.8×106 viable CD34+ cells were reproducibly generated as the final product from 220 mL whole blood containing 17.1±8.1x106 viable CD34+ cells. CD34+ identity, genetic stability and telomere length were consistent with those of basal CD34+ cells. Gram staining and mycoplasma and endotoxin analyses were negative in all cases. We confirmed the therapeutic efficacy of both CD34±cell categories in experimental AMI (Acute Myocardial Infarct) in immuno-deficient rats during pre-clinical studies. Discussion: This reproducible, automated, and standardized expansion process produces high numbers of CD34+ cells corresponding to the approved ATMP and paves the way for a phase I/IIb study in AMI, which is currently recruiting patients.
Biography:
Omid Panahi has completed his Graduation from Centro Escolar University on Doctor of Dental Medicien and MSc in Oral and Maxillofacial surgery from Yeditepe University, Istanbul, Turkey. He has published more than 40 papers in reputed journals and has been serving as an Editorial Board Member of ISI journals.
Abstract:
Stem cells are unique cells and reproducible cells that can be useful as a good alternative to future therapies in the field of dentistry as well as oral surgeries in the mouth. The aim of the present study was to investigate the stem cells type, characteristics and benefits of the stem cells and its role in modern dentistry. With online search about stem cells and regenerative dentistry in dental and medicine journals to retrieve clinical and experimental studies, case reports and review articles by using keywords: dental stem cells, future dentistry. The future of modern dentistry can be regenerative stem cell-based for oral and dental care, which will be used by patients own stem cells to treat the disease.
Pamela Klecki
Karolinska Institute, Sweden
Title: Heterogeneity of sympatho-adrenal system reveals new possible origin of neural-crest derived tumors
Biography:
Pamela Klecki has completed her Graduation in from University of Vienna. She is currently pursuing her Masters in both Tissue Engineering and Regenerative Medicine at the University of Applied Sciences Technikum Wien and in the Experimental and Medical Biosciences at Linkoping University in Sweden
Abstract:
Adrenergic chromaffin cells of the adrenal medulla are generated through recruitment of nerve- associated neural crest-derived cells termed Schwann cell precursors (SCPs). The present study evaluates the effect of serotonin precursor (5-HTP) on survival and proliferation of neural crest derived progenitors into chromaffin cells on E13.5 explants derived from C57BL/6 wild type mice. We also investigate whether serotonin (5-HT) enhances neurite outgrowth and proliferation in non differentiated rat pheochromocytoma cells (PC12), which originate from chromaffin cells. Here we report that treatment with serotonin precursors resulted in a significant decrease of proliferating tyrosine hydroxylase positive (TH+) cells in the adrenal gland (AG). In addition, we demonstrated that serotonin enhances neurite outgrowth in non differentiated cells. The preliminary data indicate the potential of serotonin to function as a new molecular target for neural crest-derived tumors as pheochromocytoma.